RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Other Events
Item 8.01. Other Events.
On July 11, 2019, Ritter Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it had received written notice from Nasdaq that the Company’s minimum bid price deficiency has been cured and that the Company is in compliance with all applicable listing standards. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release dated July 11, 2019, entitled “Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement – Ritter Shares Will Continue to Trade on the Nasdaq Capital Market” |
RITTER PHARMACEUTICALS INC Exhibit
EX-99.1 2 ex99-1.htm Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES (July 11,…
To view the full exhibit click here
About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.
